Clinical Progress AlgoTx is a clinical stage biotech advancing ATX01 for chemotherapy-induced peripheral neuropathy with a Phase II trial results expected in early 2025 and plans for a potential Phase III, signaling near-term opportunity for strategic partners, CROs, and pharma collaborators.

Non-Opioid Frontier ATX01 is a non-opioid, locally acting topical therapy targeting nociceptive sodium channels, aligning with payer and provider priorities to reduce opioid use and improve CIPN management, presenting a compelling value proposition for pain management portfolios.

Strong Backing The company has secured EUR 35 million in total funding, including a EUR 20 million Series B led by Relyens Innovation Santé / Turenne Capital, with a diverse investor base and an experienced leadership team, indicating readiness for partnered development and co-investment discussions.

ESG Adjacency Awarded France Biotech’s ESG HealthTech Trophy in 2023, highlighting a commitment to ESG and sustainable healthcare innovation, which can resonate with impact-focused funds, strategic investors, and governments seeking responsible biotech partnerships.

Global Trial Exposure The international Phase II trial involves over 270 patients, creating opportunities for global CROs, site networks, and potential expansion partnerships in Europe and beyond as the program advances toward late-stage studies.